EIB financing strengthens F2G´s research and innovation Financing is provided under the InnovFin Infectious Diseases Finance Facility (IDFF) funded by Horizon 2020, the EU’s research and innovation programme The European Investment Bank (EIB) is lending EUR 24 million to Austrian F2G Biotech GmbH, a research-intensive company, focusing on the discovery and development of novel drugs […]
MANCHESTER, UK – 09 January 2017 – F2G Ltd, a UK Biotech developing novel therapies for life threatening fungal infections, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted orphan drug status to its lead clinical candidate, F901318, for the treatment of invasive Aspergillosis and rare mould infections caused
F2G Ltd Receives European Orphan Drug Designation for its Lead Candidate F901318 Read More »
MANCHESTER, UK – 05 December 2016 – F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of John H. Rex, MD, FACP to the position of Chief Medical Officer, effective from 2nd November 2016. Dr Rex is a distinguished research scientist and a key opinion leader in the field of
F901318 represents a novel class of antifungal drug, the orotomides Currently in clinical development for the treatment of invasive aspergillosis MANCHESTER, UK – 26 October 2016 – F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the publication of the initial F901318 data in the prestigious scientific journal Proceedings of the National
F2G Ltd announces publication of initial F901318 data in scientific journal PNAS Read More »
MANCHESTER, UK – 11 July 2016 – F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ralf Schmid to the position of Chief Financial Officer, effective from 4th July 2016. Ralf brings over 20 years’ experience to F2G, with considerable expertise in M&A, licensing, public and private market transactions.
Funding to Take Lead Compound Through to Product Approval and Development of Pipeline Assets MANCHESTER, UK – 20 June 2016 – F2G Ltd, the UK-based antifungal drug discovery and development company, today announced that it has raised $60 million in financing to develop its pipeline of novel therapies to treat life threatening invasive fungal infections.
